CA3082363A1 - Benzenesulfonamide derivatives and pharmaceutical compositions thereof useful as ire1 small molecule inhibitors - Google Patents
Benzenesulfonamide derivatives and pharmaceutical compositions thereof useful as ire1 small molecule inhibitors Download PDFInfo
- Publication number
- CA3082363A1 CA3082363A1 CA3082363A CA3082363A CA3082363A1 CA 3082363 A1 CA3082363 A1 CA 3082363A1 CA 3082363 A CA3082363 A CA 3082363A CA 3082363 A CA3082363 A CA 3082363A CA 3082363 A1 CA3082363 A1 CA 3082363A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- amino
- compound
- solvate
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762584575P | 2017-11-10 | 2017-11-10 | |
| US62/584,575 | 2017-11-10 | ||
| US201862678723P | 2018-05-31 | 2018-05-31 | |
| US62/678,723 | 2018-05-31 | ||
| PCT/US2018/059894 WO2019094641A1 (en) | 2017-11-10 | 2018-11-08 | Ire1 small molecule inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3082363A1 true CA3082363A1 (en) | 2019-05-16 |
Family
ID=64477302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3082363A Pending CA3082363A1 (en) | 2017-11-10 | 2018-11-08 | Benzenesulfonamide derivatives and pharmaceutical compositions thereof useful as ire1 small molecule inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10745379B2 (enExample) |
| EP (1) | EP3707126B1 (enExample) |
| JP (3) | JP7271538B2 (enExample) |
| CN (1) | CN111566089B (enExample) |
| CA (1) | CA3082363A1 (enExample) |
| WO (1) | WO2019094641A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| AU2018278311B2 (en) * | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| WO2019094641A1 (en) | 2017-11-10 | 2019-05-16 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
| JP7546299B2 (ja) | 2018-12-03 | 2024-09-06 | コーネル・ユニバーシティー | Ｉｒｅ１小分子阻害物質 |
| US20220265656A1 (en) * | 2019-05-15 | 2022-08-25 | Cornell University | Combination therapies with ire1 small molecule inhibitors |
| EP3983400B1 (en) * | 2019-06-11 | 2025-05-28 | Genentech, Inc. | Quinazolinyl compounds and methods of use |
| JP2021031420A (ja) * | 2019-08-21 | 2021-03-01 | 日東電工株式会社 | Ｍｙｈ９の阻害物質を用いた、がん転移抑制 |
| US20240262830A1 (en) * | 2020-02-03 | 2024-08-08 | Nimbus Iaso, Inc. | Ire1a modulators and uses thereof |
| CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| PE20231311A1 (es) | 2020-11-18 | 2023-08-24 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |
| CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
| MX2024006627A (es) | 2021-12-03 | 2024-08-22 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos. |
| US20250263400A1 (en) * | 2022-04-08 | 2025-08-21 | Alesta Therapeutics BV | Gcn2 modulator compounds |
| GB202207721D0 (en) | 2022-05-25 | 2022-07-06 | Cerevance Ltd | Novel Compounds |
| AU2024356374A1 (en) * | 2023-10-06 | 2026-04-16 | Alesta Therapeutics BV | Compounds of gcn2 modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US8980899B2 (en) * | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| MX2012011504A (es) * | 2010-04-05 | 2013-01-18 | Mannkind Corp | Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa). |
| US9422298B2 (en) | 2011-03-17 | 2016-08-23 | Cmg Pharmaceutical Co., Ltd. | Pyridopyrimidine derivatives and use thereof |
| CA2886240A1 (en) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation of ire1 |
| WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| WO2016022839A1 (en) * | 2014-08-06 | 2016-02-11 | The Regents Of The University Of California | Modulators of ire1 |
| AU2017228398A1 (en) | 2016-03-03 | 2018-10-18 | Cornell University | Small molecule IRE1-alpha inhibitors |
| AU2018278311B2 (en) | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| WO2019094641A1 (en) | 2017-11-10 | 2019-05-16 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
-
2018
- 2018-11-08 WO PCT/US2018/059894 patent/WO2019094641A1/en not_active Ceased
- 2018-11-08 CN CN201880085863.XA patent/CN111566089B/zh active Active
- 2018-11-08 US US16/184,916 patent/US10745379B2/en active Active
- 2018-11-08 EP EP18808592.2A patent/EP3707126B1/en active Active
- 2018-11-08 CA CA3082363A patent/CA3082363A1/en active Pending
- 2018-11-08 JP JP2020526066A patent/JP7271538B2/ja active Active
-
2020
- 2020-07-16 US US16/931,203 patent/US10961218B2/en active Active
-
2021
- 2021-02-15 US US17/175,940 patent/US11634403B2/en active Active
-
2023
- 2023-02-28 US US18/176,362 patent/US12071424B2/en active Active
- 2023-04-26 JP JP2023071977A patent/JP7535335B2/ja active Active
-
2024
- 2024-06-27 US US18/757,200 patent/US20240425477A1/en active Pending
- 2024-07-29 JP JP2024122258A patent/JP2024156774A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220251065A1 (en) | 2022-08-11 |
| US10961218B2 (en) | 2021-03-30 |
| CN111566089A (zh) | 2020-08-21 |
| US20200392106A1 (en) | 2020-12-17 |
| EP3707126B1 (en) | 2025-05-14 |
| JP2021502387A (ja) | 2021-01-28 |
| EP3707126A1 (en) | 2020-09-16 |
| US20240425477A1 (en) | 2024-12-26 |
| WO2019094641A1 (en) | 2019-05-16 |
| US20190169160A1 (en) | 2019-06-06 |
| US20230271935A1 (en) | 2023-08-31 |
| JP7271538B2 (ja) | 2023-05-11 |
| US10745379B2 (en) | 2020-08-18 |
| US12071424B2 (en) | 2024-08-27 |
| JP2023100744A (ja) | 2023-07-19 |
| US11634403B2 (en) | 2023-04-25 |
| JP2024156774A (ja) | 2024-11-06 |
| CN111566089B (zh) | 2023-11-17 |
| JP7535335B2 (ja) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12071424B2 (en) | IRE1 small molecule inhibitors | |
| US11649224B2 (en) | IRE1 small molecule inhibitors | |
| US11337970B2 (en) | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | |
| TW201718597A (zh) | Ｈｐｋ１抑制劑及其使用方法 | |
| CA3121755A1 (en) | Ire1 small molecule inhibitors | |
| KR20100093552A (ko) | 단백질 키나제 ｃ-세타로서의 [1ｈ-피라졸로[3,4-ｂ]피리딘-4-일]-페닐 또는 -피리딘-2-일 유도체 | |
| WO2018222917A1 (en) | Ire1 small molecule inhibitors | |
| US12479818B2 (en) | Treatment of fibrosis with IRE1 small molecule inhibitors | |
| WO2020232401A1 (en) | Combination therapies with ire1 small molecule inhibitors | |
| EP4568957A1 (en) | Substituted phenyl oxooxazolyl piperidine dione compounds | |
| EP4201924B1 (en) | Ire1 small molecule inhibitors | |
| WO2024233514A1 (en) | Substituted phenyl oxazolone compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241101 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241101 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241101 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241106 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250207 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250909 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250924 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250924 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250924 |